You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 38 No. 9, September 1981 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Plasmapheresis in Idiopathic Inflammatory Myopathy

Experience With 35 Patients

Peter C. Dau, MD

Arch Neurol. 1981;38(9):544-552.


Abstract

• Thirty-five patients with idiopathic inflammatory myopathy (IM) were treated with plasmapheresis. They had had inadequate clinical responses to prednisone or to prednisone and cytotoxic immunosuppressive drug therapy. All patients received cyclophosphamide or chlorambucil in addition to plasmapheresis; 33 also received prednisone. Strength increased in 32 patients during combined therapy; patients with the most active disease experienced substantial improvement that approached clinical remission in some cases. Clinical improvement was documented by muscle testing, forced vital capacity, electromyography, muscle biopsy, and serum creatine phosphokinase activity. The major side effect of treatment was herpes zoster. Primary biliary cirrhosis improved in one patient. Although the effects of plasmapheresis cannot be dissociated from those of the concomitantly administered immunosuppressive drugs, the improvement seen in patients with active disease suggests that plasmapheresis with immunosuppressive drug therapy may find a place in their treatment and implicates circulating factors in the pathogenesis of IM.



Author Affiliations

From the Paul M. Aggeler Memorial Laboratory, Children's Hospital of San Francisco, and the Department of Medicine, University of California, San Francisco.


Footnotes

Accepted for publication Dec 31, 1980.

Read in part at the Workshop on Therapeutic Plasma and Cytapheresis, Rochester, Minn, April 26, 1979.

Reprint requests to Paul M. Aggeler Memorial Laboratory, Children's Hospital of San Francisco, PO Box 3805, San Francisco, CA 94119 (Dr Dau).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evaluation and treatment of inflammatory myopathies
Amato and Barohn
J. Neurol. Neurosurg. Psychiatry 2009;80:1060-1068.
ABSTRACT | FULL TEXT  

Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis
Danieli et al.
Ann Rheum Dis 2002;61:37-41.
ABSTRACT | FULL TEXT  

Treatment of dermatomyositis and polymyositis
Choy and Isenberg
Rheumatology (Oxford) 2002;41:7-13.
ABSTRACT | FULL TEXT  

Current Concepts in the Idiopathic Inflammatory Myopathies: Polymyositis, Dermatomyositis, and Related Disorders
Plotz et al.
ANN INTERN MED 1989;111:143-157.
ABSTRACT  

Plasmapheresis: Therapeutic or Experimental Procedure?
Dau
Arch Neurol 1984;41:647-653.
ABSTRACT  

Plasma Exchange in Neurologic Diseases
Lisak
Arch Neurol 1984;41:654-657.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1981 American Medical Association. All Rights Reserved.